The global Psoriasis Drugs Market size is expected to be valued at USD 21.11 billion by 2022, as per
a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during
the forecast period. Rising disease awareness, increasing number of
reimbursement strategies for biologics, and advanced diagnostic and
technological tools are likely to increase the adoption of psoriasis
therapeutics.
Additionally, expanding base of patients suffering
from psoriasis is anticipated to fuel growth prospects. The exact causative
factors for psoriasis are undetermined; however, certain genetic and
environmental factors may trigger the disease onset. Most available treatments
aim to decelerate disease progression by stopping hyperproliferation of
keratinocyte.
Psoriasis can be classified into five types: plaque,
guttate, inverse, pustular, and erythrodermic. The types vary in terms of site
of disease and characterization of lesions. Erythrodermic psoriasis is the
rarest and plaque psoriasis is the most prevalent type affecting patients all
over the world.
Incidence rate of psoriasis has witnessed a gradual
rise over the years across various geographical locations. This increase can be
attributed to genetic and environmental triggers as well as lifestyle changes.
Rise in prevalence rates could also be associated with declining response or
developing resistance to therapies for disease control.
Browse
Details of Report @
https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market
https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market
Further key findings from the report suggest:
- Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing
to its higher usage by healthcare practitioners and easy availability
- TNF-inhibitors are likely to lose market shares over the forecast
period due to increasing preference for IL-inhibitor therapy to
conventional TNF-inhibitors
- Interleukin-inhibitors is expected to register a lucrative CAGR of
over 21.0% during the forecast period owing to improved safety and
efficacy profiles of Interleukin-inhibiting drugs
- The U.S is the dominant region in the psoriasis market in terms of
revenue in 2016 due to increasing number of patients seeking treatment and
presence of well-established healthcare services
- Japan is expected to be the fastest growing region during the same
period due to growing awareness about the disease among the populace
- Some of the key players in this industry are AbbVie Inc.; Amgen
Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca;
Celgene Corporation; UCB; and Merck.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment